Montana’s push to become a hub for experimental medicine has taken a major step forward. The state now offers biotech companies a defined route to sell experimental drugs to consumers, even when those products have only completed very early testing.
Under the framework described this week, companies whose drugs have gone through preliminary trials can apply for access through a newly established state board. In some cases, that early testing may involve as few as 10 healthy people. Applicants must also pay a $12,500 fee to have their case reviewed.
The board is part of Montana’s broader effort to create a market for treatments that have not yet gone through the full federal approval process. According to the available details, the panel includes Montana-licensed doctor James Burke, an oncologist, and bioethicist Jessica Flanigan.
Supporters see the move as a way to speed access to promising therapies and attract biotech business to the state. Critics are likely to focus on the limited evidence behind such drugs at this stage, since early testing is typically designed to assess basic safety rather than prove how well a treatment works.
